Colin Hirst, MD
Interventional Cardiology · Albany, NYNPI 1235493123
Payments from drug & device makers
Across 485 payments — averaging $134.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$34K
- Edwards Lifesciences$17K
- Abbott$5K
- Abiomed$3K
- Boston Scientific$1K
- Cathworks, Inc.$818
- plus $4K from 27 others
Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$2K
What the payments were for
- Consulting fees$7,42011%
- Grants$28,00043%
- Travel & lodging$10,97317%
- Food & beverage$18,84429%
- Education$90%
- Entertainment$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 58 | $33,999 |
| Edwards Lifesciences | 149 | $17,278 |
| Abbott | 52 | $4,536 |
| Abiomed | 41 | $3,143 |
| Boston Scientific | 26 | $1,330 |
| Cathworks, Inc. | 6 | $818 |
| Boehringer Ingelheim | 22 | $508 |
| Shockwave Medical, Inc | 3 | $359 |
| Novartis | 20 | $357 |
| Pfizer | 16 | $337 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $273 |
| Saranas, Inc. | 3 | $264 |
| Inari Medical, Inc. | 5 | $239 |
| Amgen | 13 | $230 |
| Opsens Inc. | 2 | $226 |
| Cardiva Medical, Inc. | 22 | $223 |
| Chiesi USA, Inc. | 8 | $202 |
| W. L. Gore & Associates, Inc. | 2 | $171 |
| Penumbra, Inc. | 1 | $125 |
| Terumo Medical Corporation | 5 | $121 |
| AstraZeneca | 6 | $99 |
| E.r. Squibb & Sons, L.L.C. | 4 | $80 |
| Livanova USA, Inc. | 1 | $80 |
| Regeneron Healthcare Solutions, Inc. | 3 | $59 |
| Biosense Webster, Inc. | 2 | $48 |
| Johnson & Johnson | 1 | $31 |
| Teleflex LLC | 2 | $30 |
| Truvic Medical, Inc. | 1 | $28 |
| Angiodynamics, Inc. | 1 | $24 |
| Bridgebio Pharma, Inc. | 1 | $23 |
| Portola Pharmaceuticals, LLC | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Cardiovascular Systems Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$13,802
- Edwards SAPIEN 3 Transcatheter Heart Valve$8,341
- COREVALVE EVOLUT R$3,115
- Impella$2,102
- Ultreon$1,262
- FFRangio$730
- WATCHMAN Access System$468
- TRICLIP$455
- WATCHMAN FLX$418
- XIENCE SIERRA$410
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$359
- OPTIS$274
- CardioMEMS HF System$270
- AMPLATZER$184
- OptoWire$177
- PRESSUREWIRE$177
- AMPLATZER Occluders$152
- ABSOLUTE PRO$140
- HeartMate 3 Left Ventricular Assist Device$139
- KENGREAL$136
How this compares
$65,295 in reported general payments places this provider in the 75th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 97 | $138,375 |
| EntrestoSacubitril/Valsartan | 67 | $94,007 |
| Repatha SureclickEvolocumab | 79 | $66,306 |
| JardianceEmpagliflozin | 17 | $28,359 |
| XareltoRivaroxaban | 14 | $21,343 |
| BrilintaTicagrelor | 18 | $11,312 |
| Praluent PenAlirocumab | 17 | $10,162 |
| Metoprolol Succinate | 185 | $2,725 |
| Ranolazine ErRanolazine | 19 | $2,662 |
| Ezetimibe | 68 | $2,515 |
| Atorvastatin Calcium | 233 | $2,247 |
| ClopidogrelClopidogrel Bisulfate | 166 | $1,645 |
| Rosuvastatin Calcium | 86 | $1,562 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 36 | $1,300 |
| Irbesartan | 22 | $1,237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $337 | $138,37597 claims |
| NovartisEntresto | $357 | $94,00767 claims |
| Boehringer IngelheimJardiance | $508 | $28,35917 claims |
| Johnson & JohnsonXarelto | $31 | $21,34314 claims |
| AstraZenecaBrilinta | $99 | $11,31218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in Albany
- Martin LeonNew York$13.5M
- David CohenRoslyn$9.8M
- Susheel KodaliNew York$6M
- Mohamed Azeem LatibBronx$4.6M
- Richard ShlofmitzRoslyn$4.5M
- Deepak BhattNew York$4.1M
- Samin SharmaNew York$3.7M
- Annapoorna KiniNew York$3.5M
- Sahil ParikhNew York$2.7M
- George DangasNew York$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.